Corcept Therapeutics Initiates CATALYST Clinical Trial
<!-- Name:DistributionId Value:8797160 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Corcept
Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral…
MENLO PARK, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications…
Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent,…
MENLO PARK, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications…
Corcept Therapeutics Announces Appointment of Three Senior Leaders
MENLO PARK, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to…
Corcept Therapeutics Completes Enrollment in Phase 2 GRATITUDE Study of Miricorilant…
MENLO PARK, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to…
Corcept Therapeutics to Host Ovarian Cancer Program Update on Thursday, March 31,…
MENLO PARK, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will host an event for investors and analysts on Thursday, March…